BridgeBio Oncology Therapeutics, Inc.

BridgeBio Oncology Therapeutics, Inc. (Nasdaq: BBOT) is a blank check company that completed its initial public offering in 2023, targeting acquisition opportunities in the oncology and therapeutics sector. Sponsored by an affiliate of BridgeBio Pharma, the SPAC is focused on identifying a business combination within the life sciences and biopharmaceutical space, with a particular emphasis on oncology. The company filed a Form 10-Q with the Securities and Exchange Commission on May 15, 2024, covering its quarterly financial position as it continues to search for a suitable merger target. BBOT remains in the pre-combination phase as of the filing date. Visit SpacDesk and sign up for full data, filings, and deal-tracking on BBOT and hundreds of other active SPACs.